Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBIT (2016 - 2025)

Historic EBIT for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $4.1 million.

  • Zevra Therapeutics' EBIT rose 11517.25% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.7 million, marking a year-over-year decrease of 107.21%. This contributed to the annual value of -$87.0 million for FY2024, which is 7539.51% down from last year.
  • Zevra Therapeutics' EBIT amounted to $4.1 million in Q3 2025, which was up 11517.25% from -$71.0 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year EBIT high stood at $7.0 million for Q1 2021, and its period low was -$71.0 million during Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' median EBIT value was -$9.1 million (recorded in 2022), while the average stood at -$12.8 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 28437.09% in 2021, then crashed by 59020.98% in 2023.
  • Zevra Therapeutics' EBIT (Quarter) stood at -$2.8 million in 2021, then tumbled by 221.67% to -$9.1 million in 2022, then tumbled by 65.8% to -$15.2 million in 2023, then decreased by 1.71% to -$15.4 million in 2024, then soared by 126.87% to $4.1 million in 2025.
  • Its EBIT stands at $4.1 million for Q3 2025, versus -$71.0 million for Q2 2025 and -$5.4 million for Q1 2025.